Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | CTSD | P07339 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053080 | 0.89 | OPRD1 (0.56) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30646297 | 0.88 | CTSD (0.55) | OPRD1OPRM1CTSD | |
| SCHEMBL3052110 | 0.87 | CTSD (0.57) | CTSDANPEPMMEACECPA1 | |
| SCHEMBL3052108 | 0.87 | CTSD (0.57) | CTSDANPEPMMEACECPA1 | |
| SCHEMBL31411848 | 0.87 | CTSD (0.54) | OPRD1OPRM1OPRK1CTSDMME | |
| SCHEMBL31462081 | 0.86 | OPRD1 (0.51) | OPRD1OPRM1OPRK1CTSD | |
| SCHEMBL29445339 | 0.86 | OPRD1 (0.66) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29448576 | 0.86 | OPRD1 (0.55) | OPRD1OPRM1OPRK1CTSD | |
| SCHEMBL3863306 | 0.86 | OPRD1 (0.57) | OPRD1OPRM1OPRK1CTSD | |
| SCHEMBL31462339 | 0.85 | CTSD (0.60) | CTSDANPEPMMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | OPRD1 402/4885OPRM1 804/4885OPRK1 2117/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | OPRD1 2937/4885OPRM1 2130/4885OPRK1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.